Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs Medpace Holdings Inc (MEDP) Price & Performance

CAVA Group IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs Medpace Holdings Inc — how do they compare? CAVA Group Inc trades at $69.74 (market cap $8.15B), while Medpace Holdings Inc trades at $530.41 (market cap $15.31B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.

CAVAMEDP
Market Cap
$8.15B$15.31B
Sector
Consumer CyclicalTechnology
52-Week High
$97.39$620.59
52-Week Low
$43.59$308.88
Enterprise Value
$8.25B$14.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA trades at $72.54, up 0.5% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong revenue growth and expansion momentum, but faces high valuation multiples and margin pressures. Recent news highlights aggressive store openings and technology investments driving traffic, though the stock has experienced volatility amid market fluctuations.

Outlook remains growth-focused with analyst consensus bullish, targeting $94.73, but risks include elevated P/E of 134.56, competitive pressures, and potential margin compression from expansion costs. The stock offers upside if execution continues, but requires careful monitoring of profitability trends.

Medpace Holdings Inc

MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.

Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP